No title
Today immunohistochemistry (IHC) stains molecular biomarkers for treatment stratification. IHC can become increasingly objective by improving sensitivity, quantification and multiplexing capabilities. We use upconverting nanoparticles to achieve this, potentially leading to improved treatment outcomes.
